-
Bridging Diagnosis And Therapy Through Innovative Radiopharmaceuticals Bringing Precision Medicine To Every Patient
-
Committed To Becoming A Global LeaderIn PrecisionRadiopharmaceuticalInnovation
-
Life First Science Driven Pursuit of Excellence Relentless Execution Collaborative Win-Win Breakthrough Innovation
About Us
Chengdu StarRay Therapeutics Co., Ltd.
Chengdu StarRay Therapeutics Co., Ltd. was established on August 22, 2025, in Chengdu Tianfu International Bio-Town.. As Fosun Pharma’s innovation platform dedicated to radiopharmaceuticals, StarRay was founded and is led by a team of accomplished scientists with extensive international experience and a global perspective. With radioligand therapy (RLT) at the core of its strategy, the company focuses primarily on the research, development, and clinical translation of theranostic radiopharmaceuticals for oncology. StarRay is building comprehensive capabilities across core radiopharmaceutical technologies, product development, and commercial-scale manufacturing, with the goal of establishing an innovation-driven, globally competitive radiopharmaceutical technology platform and developing high-value diagnostic and therapeutic products.
R&D Pipeline
Focusing on the field of pan oncology Integrated diagnosis and treatment nuclear medicine
With radioligand therapy (RLT) at the core of its strategy, StarRay focuses on the discovery, development, and clinical translation of theranostic radiopharmaceuticals for oncology. The Company continuously advances the development of a differentiated R&D pipeline, and is committed to delivering safe, precise, and accessible diagnostic and therapeutic solutions to patients worldwide.
News
Explore the latest news & reports
-
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
2026-04-28
(28 April 2026, Shanghai, China) On 28 April, Fosun Pharma (“the Company”, stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy.
-
Fosun Pharma Announces 2025Q3 Financial Results Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025
2025-10-28
(October 28, 2025, Shanghai, China)– On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to shareholders of RMB2,523 million.
Career
Build a platform for talent growth and development
-
Staff & Culture
StarRay is committed to fostering a culture of inspiration, curiosity and empowerment.
-
Join us
Focused on radiopharmaceuticals innovation, we offer diverse career opportunities and growth pathways. We empower employees to achieve personal value and jointly fuel the company’s long term growth.
